Bullish
Relmada Highlights NDV-01 Phase 2 Data, Phase 3 Plans
Relmada Therapeutics announced strong 12-month Phase 2 data for NDV-01 in bladder cancer, with complete response rates up to 95% and durable responses...
RLMD
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (1)
Neutral (0)
Bearish (0)
Latest RLMD News
Bullish
Research RLMD on:
Ad Space